Categories Consumer, Earnings Call Transcripts, Preliminary Transcripts

Helen of Troy Limited (HELE) Q2 2022 Earnings Call Transcript

HELE Earnings Call - Preliminary Transcript

Helen of Troy Limited (NASDAQ: HELE) Q2 2022 earnings call dated Oct. 07, 2021

Presentation:

Operator

Greetings. Welcome to Helen of Troy Ltd’s Second Quarter 2022 Earnings Call. [Operator Instructions] Please note this conference is being recorded.

I will now turn the conference over to Jack Jancin, Senior Vice President of Corporate Business Development. Thank you. You may begin.

To read the full story, subscribe to AlphaStreet's FREE membership.

Join Now

Why FREE membership?

  • It allows you to highlight any particular content/data in the earnings call transcripts, add your insights, and share it seamlessly within your community
  • You can access preliminary earnings call transcripts during the the call, that is, in real time!
  • Track your favorite stocks and receive customized email alerts in your Inbox to keep you updated about any information regarding them

Already a member? Sign In now

Disclaimer

This transcript is produced by AlphaStreet, Inc. While we strive to produce the best transcripts, it may contain misspellings and other inaccuracies. This transcript is provided as is without express or implied warranties of any kind. As with all our articles, AlphaStreet, Inc. does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company’s SEC filings. Neither the information nor any opinion expressed in this transcript constitutes a solicitation of the purchase or sale of securities or commodities. Any opinion expressed in the transcript does not necessarily reflect the views of AlphaStreet, Inc.

© COPYRIGHT 2021, AlphaStreet, Inc. All rights reserved. Any reproduction, redistribution or retransmission is expressly prohibited.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top